Cerbios- Pharma SA

Barbengo/Lugano, 
Switzerland
http://www.cerbios.ch
  • Booth: 1301

Cerbios is a privately held company that specializes in the development and manufacture of both chemical and biological APIs for its partners world-wide. Exclusive, third-party manufacturing services are offered by - the Chemical Division for High Potency Active Ingredients (HPAIs) including Category 4 SafeBridge (<10ng/m3), Antibody Drug Conjugates (ADC) -the Biological Division for mAbs, rec Proteins and pharma probiotics. Full CMC support is provided to our partners. Supply of cGMP batches from pre-clinical to commercial. Paramount to this is the expertise to provide all of the documentation and support necessary for a successful world-wide registration. Our Vision: “To provide excellent services, helping our partners to achieve their core business objectives“. Our Mission: “To be a leading company in distinctive chemical and biological API products and services”. Our Motto: "Fostering Value through Innovation".


 Products

  • Antibody Drug Conjugates (ADCs)
    Within the PROVEO collaborative partnership, Cerbios will perform process development and manufacture of the cytotoxic drug-linker payload, and the subsequent conjugation to the monoclonal antibody to produce the ADC drug substance....

  • Within the PROVEO collaborative partnership, Cerbios will perform process development and manufacture of the cytotoxic drug-linker payload, and the subsequent conjugation to the monoclonal antibody to produce the ADC drug substance.

    The above mentioned services in combination with monoclonal antibody production by CMC Biologics and sterile filling of the ADC drug product by Oncotec, along with analytical and quality services throughout the PROVEO supply chain, as well as secondary packaging through to ready-to-sell final drug product by IDT Biologika will be available to clients beginning in 2017 and will further enhance PROVEO`s full ADC service offering.

    Development and manufacturing of

    1. Monoclonal antibody (alliance partner or small scale in-house)
    2. Payloads (Linker + Cytotoxic Warhead)
    3. Conjugation
    4. Formulation development and Fill & Finish (alliance partner)
    5. Labeling and packaging (alliance partner)

    Cerbios has internal capabilities and expertise to manufacture single components of the ADC, along with the conjugation process, as well as the flexibility to run the conjugation between payload and mAbs coming from third party manufacturers.

    About ADCs
    Antibody-drug conjugates (ADCs) belong to a new class of compounds conceived as targeted therapy for the treatment of cancer.

    A typical ADC consists of three components: a monoclonal antibody chemically bond to a cytotoxic drug by a specific linker.

    The antibody selectively targets a tumor cells (usually a protein that, ideally, is only to be found in or on tumor cells) and attaches to its surface. The interaction between the antibody and the antigen (the target protein) generates the absorption and internalization of the antibody together with the cytotoxin within the tumor cell and, subsequently, the cytotoxic drug is released to kills the same cancer cell.

    Nowadays different innovative pharmaceutical companies are applying these complex technologies to develop new targeted oncology products with higher safety profile.

    Leveraging the synergies of Cerbios Chemical and Biological Divisions and a natural evolution of established competence in the Monoclonal Antibodies (mAbs) and in the Highly Potent Active Ingredient (HPAIs) process development and cGMP manufacturing, Cerbios offers process development and manufacturing services for Antibody Drug Conjugates (ADCs).